Safety and efficacy of interferon γ in friedreich's ataxia

Mov Disord. 2020 Feb;35(2):370-371. doi: 10.1002/mds.27979. Epub 2020 Jan 13.

Authors

Marinela Vavla¹, Maria Grazia D'Angelo¹, Filippo Arrigoni¹, Nicola Toschi^{2

3}, Denis Peruzzo¹, Sandra Gandossini¹, Annamaria Russo¹, Eleonora Diella¹, Stefania Tirelli¹, Roberto Salati¹, Paolo Scarpazza¹, Riccardo Luffarelli^{2

4}, Silvia Fortuni², Alessandra Rufini^{2

4}, Ivano Condò², Roberto Testi^{2

4}, Andrea Martinuzzi¹

Affiliations

¹ IRCCS E. Medea Scientific Institute, Conegliano, (TV), Italy.
² Department of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.
³ Athinoula A. Martinos Center for Biomedical Imaging, Harvard Medical School, Boston, Massachusetts, USA.
⁴ Fratagene Therapeutics, Rome, Italy.

PMID: 31930551
DOI: 10.1002/mds.27979

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Female
Friedreich Ataxia / drug therapy*
Friedreich Ataxia / genetics
Humans
Interferon-gamma / pharmacology*
Male
Phenotype
Safety*
Trinucleotide Repeats / drug effects*

Substances

Interferon-gamma